関連する実験動画
Updated: Sep 10, 2025

08:42
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
4.6K
STAT3は,突然変異したKRAS除去後に腫瘍発生性を維持する
Stephen D'Amico1,2, Varvara Kirillov1, Jingxuan Liu3,4
1Department of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, 11794, USA.
EMBO reports
|August 26, 2025
まとめ
STAT3は,臓がんにおけるKRAS不活性化後の腫瘍の成長をサポートする. STAT3とKRASの両方をブロックすると,がん細胞のアイデンティティが破壊され,腫瘍の成長が妨げられ,クリアランスが促進されます.
科学分野:
- 腫瘍学
- 分子生物学
- 癌 の 遺伝
背景:
- 腫瘍性KRAS変異は致命的なヒトがんの原動力です
- KRASの無効化は,裏付けメカニズムが不明で,変化する結果と抵抗を生み出します.
- 効果的ながん治療には 抵抗性の理解が不可欠です
研究 の 目的:
- KRASの枯渇後の腫瘍の持続性におけるSTAT3の役割を調査する.
- STAT3 が KRAS 消去されたがんにおける腫瘍発生性を支持するメカニズムを解明する.
- KRASの阻害によるKRAS変異がんの脆弱性を特定する.
主な方法:
- 臓管内腺がんのモデルにおける変異KRASのCRISPR媒介の除去
- 生き残った癌細胞のSTAT3依存性を評価する機能的測定法.
- トランスクリプション・プロフィール 破壊されたコア・プログラムを特定する
- 腫瘍の成長と免疫反応を評価するためにマウスでのin vivo研究.
主要な成果:
- KRAS除去で生き残った癌細胞は,腫瘍発生性に関してSTAT3に依存する.
- KRASとSTAT3の結合喪失は,重要な癌細胞の転写プログラムに干渉する.
- ダブルアブレートされたモデルでは腫瘍の成長障害と免疫拒絶の強化が観察された.
- STAT3は,KRAS除去された腫瘍の悪性同一性を強制し,持続性を促進する.
結論:
- STAT3は,KRASで除去された腫瘍における腫瘍性同一性の決定的な強化剤として作用する.
- STAT3の転写プログラムは,KRASの不活性化後の悪性腫瘍を維持する.
- STAT3を標的にすることは,KRAS主導の癌における重要な脆弱性です.
- この研究は,KRAS変異性がんに対する新しい治療戦略を明らかにしています.
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K

